期刊文献+

低剂量5-Fu与Ad-IL24联用对肝癌细胞HepG2生长的抑制作用及其机制 被引量:2

Inhibition Effect of Ad-IL24 Combined with Low Dose of 5-Fu on Hepatocarcinoma Cells HepG2 and Its Mechanism
下载PDF
导出
摘要 目的探讨低剂量5-Fu与腺病毒表达的IL24联用对HepG2细胞的生长抑制作用及其机制。方法采用PCR、酶切、连接等方法构建pAd-IL24腺病毒表达载体,Western blot检测IL24蛋白水平表达情况。CCK8法确定5-Fu联用剂量,检测与Ad-IL24联用对HepG2肝癌细胞的抑制效果,并计算联合指数。流式细胞术检测不同腺病毒感染复数及不同5-Fu浓度下绿色荧光蛋白(green fluorescent protein,GFP)阳性细胞的比例。流式细胞术检测5-Fu作用前后HepG2细胞表面柯萨奇腺病毒受体(coxsackie adenovirus receptor,CAR)的表达变化。结果成功构建腺病毒表达载体pAd-IL24。确定5-Fu联用剂量为1μg/ml和2μg/ml,Ad-IL24与低剂量5-Fu联用可以协同抑制HepG2肝癌细胞生长,联合指数分别为0.75和0.64。低剂量5-Fu作用于HepG2后使其表面CAR水平显著增加(P<0.01)。结论低剂量5-Fu与Ad-IL24联用对HepG2肝癌细胞系的抑制有协同作用,可能与5-Fu上调HepG2表面CAR水平相关。 Objective To investigate the inhibition effect of Ad-IL24 combined with low dose of 5-Fu on hepatocarcinoma cells HepG2 and its mechanism. Methods PCR, restriction enzyme cleavage and linkage were used to construct the adenovirus expression vector pAd-IL24. The expression of IL24 was detected by Western blot. CCK8 assay was applied to confirm the doses of 5-Fu and to detect the viability of HepG2 cells which were treated by Ad-IL24 with or without 5-Fu. The proportion of GFP positive cells in HepG2 cells treated by different does of 5-Fu and adenovirus was detected by flow cytometry. The expression levels of coxsackie adenovims receptor (CAR) were detected by flow cytometry before and after 5-Fu treatment. Results The adenovirus expression vector pAd-IL24 was successfully constructed. The doses of 5-Fu were confirmed to be l and 2μg/ml by CCK8 assay; Ad-IL24 combined with low doses of 5-Fu synergistically inhibited the growth of HepG2 cells, and the combination index were 0.75 and 0.64 respectively. After treated with low dose of 5-Fu, the level of CAR expression on HepG2 cells was significantly increased(P〈0.01). Conclusion The combination treatment of Ad-IL24 and low dose of 5-Fu synergistically inhibit the growth of hepatocarcinoma cells HepG2, which maybe related with up-regulation of CAR induced by 5-Fu.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2016年第12期1030-1034,共5页 Cancer Research on Prevention and Treatment
基金 国家科技重大专项资助项目(2012ZX0910 2301-015)
关键词 肝癌 5氟尿嘧啶 IL24 腺病毒 柯萨奇腺病毒受体 Hepatocarcinoma 5-Fu IL24 Adenovirus Coxsackie adenovirus receptor(CAR)
  • 相关文献

参考文献2

二级参考文献27

  • 1Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014, 60(6): 2099-2108.
  • 2Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol, 2006, 24(26): 4293- 4300.
  • 3Sieghart W, Pinter M, Dauser B, et al. Erlotinib and sorafenib in an orthotopic rat model of hcpatocellular carcinoma[J]. J Hepatol, 2012, 57(3): 592-599.
  • 4Shah J, Shcn J, Liu L, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in humanhepatocellular carcinoma[J]. Hepatology, 2012, 56(3): 1004-1014.
  • 5Blivet-Van Eggelpoel MJ, Chettouh H, Fartoux L, et al. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells[J]. J Hepatol, 2012, 57(1): 108- 115.
  • 6Chen HC, Jeng YM, Yuan RH, et al. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatoceUular carcinoma and its expression predicts poor prognosis[J]. Ann Sttrg Oncol, 2012, 19(6): 2011-2019.
  • 7Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer, 2011, 47(14): 2117-2127.
  • 8Miyahara K, Nouso K, Morimoto Y, et al. Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma[J]. Hepatol Res, 2014, 44(3): 296-301.
  • 9Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy[J]. Am J Clin Oncol, 2013, 36(4): 319-324.
  • 10Ken Z, Zhu K, Kang H, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol, 2015, 33(8): 894-900.

共引文献9

同被引文献25

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部